Bio-Rad Laboratories (NYSE: BIO)
Bio-Rad Laboratories Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bio-Rad Laboratories Company Info
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
News & Analysis
This Unknown Biotech Has a Secret Weapon for Outsized Returns
Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.
3 Medical Diagnostic Stocks That Look Like Great Buys Right Now
They are coming off strong quarters, yet appear to be underpriced based on their fundamentals. Is now a good time to buy?
These 10 Healthcare Stocks Are the Biggest S&P 500 Winners of 2020
Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.
Better Buy: Exact Sciences vs. Bio-Rad Laboratories
There's a strong case to be made for both companies, but which one is a better investment?
What's Behind Bio-Rad Laboratories' Q4 Earnings Miss
Bio-Rad's Q4 revenue and earnings were disappointing, but its 2020 outlook looked good.
Here's Why 10x Genomics Rose 17.5% in December
The company scored an important win in a patent dispute.
Is This $5 Billion Biotech IPO a Buy?
10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.